MT2022-01: MSCs for ALD

Cerebral Adrenoleukodystrophy Clinical Trial

Official title:
Intravenous Administration of Mesenchymal Stem Cells (IV-MSC) for the Treatment of Cerebral Adrenoleukodystrophy (cALD)

Status Recruiting

Clinical Trial Summary

This is a single-institution study to evaluate the use of intravenously administered allogeneic, 3rd party mesenchymal stem cells (IV-MSC) in patients with active, cerebral adrenoleukodystrophy (CALD), as a bridge to hematopoietic stem cell transplant or gene therapy, or in patients who are too advanced for gene therapy or HSCT. The intervention will occur in the time between diagnosis of active CALD and transplant which is currently 8-12 weeks.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06030648
Study type	Interventional
Source	Masonic Cancer Center, University of Minnesota
Contact	Troy C Lund, MD
Phone	+1 612-626-2778
Email	lundx072@umn.edu
Status	Recruiting
Phase	Phase 1
Start date	August 28, 2023
Completion date	May 1, 2028

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04528706` - A Clinical Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT)	Phase 2
Recruiting	`NCT03789721` - Adrenoleukodystrophy National Registry Study
Withdrawn	`NCT02410239` - MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD)	Phase 1
Terminated	`NCT03367546` - Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases	Phase 2